Astellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Below 50-Day Moving Average – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $15.11 and traded as low as $15.03. Astellas Pharma shares last traded at $15.05, with a volume of 86,941 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ALPMY shares. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. Citigroup cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold”.

Astellas Pharma Price Performance

The firm has a market cap of $26.44 billion, a price-to-earnings ratio of 12.28 and a beta of 0.15. The business’s 50-day moving average price is $15.13 and its two-hundred day moving average price is $13.05. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.21 billion. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. On average, research analysts forecast that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).